A phase 3 randomized trial has shown that compared with BEACOPP, a standard seven-drug regimen for classic advanced Hodgkin lymphoma (cHL), a modified 6-drug regimen achieved progression-free survival at four years in almost 95% of patients with a shorter course and fewer side effects. The results were presented as a late-breaker at the 2024 annual meeting of the American Society of Clinical Oncology (abstract LBA7000).
Even though the BEACOPP standard is considered highly effective, the new